Jun 23, 2022
Coya Therapeutics Announces Peer-Reviewed Publication of its First-in-Class Regulatory T cell-derived Exosomes and their Therapeutic Potential in Neurodegeneration and Inflammation Related Diseases
coyatherapeutics.com
Jun 15, 2022
Coya Therapeutics Secures Option Agreement for Exclusive Worldwide Rights to Exosome Engineering Technology from Carnegie Mellon University
coyatherapeutics.com
Jun 07, 2022
Coya Therapeutics Secures $10 Million Financing to Advance Clinical and Pre-Clinical Pipeline of Regulatory T cell Therapeutics
coyatherapeutics.com
Apr 27, 2022
Coya Therapeutics Announces Annals of Neurology Publication Featuring Biomarker Data in ALS Patients Treated with Tregs Cell Therapy
coyatherapeutics.com
Apr 22, 2022
Coya Therapeutics to Participate in B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference
coyatherapeutics.com
Dec 10, 2021
Coya Therapeutics Applauds U.S. House of Representatives for Passing ACT for ALS
coyatherapeutics.com
Nov 16, 2021
Coya Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA on COYA101 for the Treatment of Amyotrophic Lateral Sclerosis
coyatherapeutics.com
Nov 01, 2021
Coya Therapeutics Appoints Dr. Adrian Hepner as Chief Medical Officer and Dr. Greg MacMichael as Chief Technical Officer
coyatherapeutics.com
Jul 14, 2021
Coya Therapeutics to Participate at the LifeSci Partners Summer Symposium
coyatherapeutics.com
Jul 07, 2021
Coya Therapeutics Receives Orphan Drug Designation from the FDA for ALS001, an Autologous Treg Cell Therapy, for the Treatment of ALS
coyatherapeutics.com
Jun 02, 2021
Coya Therapeutics to Host Key Opinion Leader Webinar on ALS001 for the Treatment of Amyotrophic Lateral Sclerosis
coyatherapeutics.com
Jun 01, 2021
Ann Lee, Ph.D., SVP at Bristol Myers Squibb, Joins Coya Therapeutics™ Board of Directors
coyatherapeutics.com
May 25, 2021
Coya Therapeutics™ Announces the Appointment of Anabella Villalobos, Ph.D. to its Board of Directors
coyatherapeutics.com
Apr 14, 2021
Coya Therapeutics™ Announces the Appointment of Hideki Garren, M.D., Ph.D., and Dov Goldstein, M.D., to Its Board of Directors
coyatherapeutics.com
Feb 23, 2021
Coya Therapeutics™ Announces Formation of Scientific Advisory Board
coyatherapeutics.com
Feb 03, 2021
Coya Therapeutics™ Completes Merger with Nicoya Health Inc. and Announces $10 Million Series A Financing to Advance Pipeline of Regulatory T cell Therapeutics Optimized for Neurodegeneration and Autoimmune Diseases
coyatherapeutics.com